Franklin Biotechnology Discovery Fund

3 / 5 Stars
Zacks Investment Research
Standard & Poor's
1 / 5 Stars
B- (Buy)

U.S. News evaluated 34 Health Funds. Our list highlights the top-rated funds for long-term investors based on the ratings of leading fund industry researchers.

See all Franklin Templeton Investments funds

See full Health rankings

See more fund rankings


The fund has returned 51.36 percent over the past year, 34.01 percent over the past three years, 27.37 percent over the past five years, and 12.90 percent over the past decade.

Trailing Returns Updated 03.31.2014
Year to date 6.8%
1 Year 51.4%
3 Years (Annualized) 34.0%
5 Years (Annualized) 27.4%
10 Years (Annualized) 12.9%

See more FRBRX performance


The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. It predominantly invests in equity securities, primarily common stock. In addition to its investments in biotechnology companies, the fund may also invest up to 20% of its net assets in equity or debt securities of any type of foreign or U.S. issuer. It is non-diversified.

See Also:

Top Franklin Templeton Investments Funds